Tamiflu (oseltamivir) isn’t dangerous for most people, but the criticisms against it are real: it shortens flu symptoms by less than a day on average, causes significant nausea and vomiting, has been linked to rare but alarming psychiatric side effects in children, and costs more than many people expect for what it delivers. The World Health Organization actually downgraded it from a “core” essential medicine to a less favorable category after reviewing the evidence. Here’s a closer look at each concern.
The Benefits Are Smaller Than Most People Think
The biggest knock against Tamiflu is that it doesn’t do what many people assume it does. A major Cochrane review, the gold standard for evaluating medical evidence, found that Tamiflu shortened flu symptoms in adults by about 16.8 hours. That means going from roughly 7 days of illness to 6.3 days. In healthy children, the reduction was slightly better at around 29 hours, but there was no measurable benefit in children with asthma.
Perhaps more importantly, the same review found that Tamiflu did not reduce the number of people admitted to the hospital or prevent flu complications. This was a key finding, because the original justification for stockpiling billions of dollars worth of the drug during pandemic planning rested partly on the assumption that it would prevent serious outcomes. A separate observational study did find reductions in pneumonia risk (15%) and hospitalization (38%), but that data came from a different study design and has been viewed with more skepticism by independent reviewers.
Based on this evidence, the WHO downgraded oseltamivir from a “core” drug to a “complementary” one, a category reserved for medications considered less cost-effective. The WHO committee recommended restricting its use to severe illness in critically ill hospitalized patients and noted that unless new supporting evidence emerged, the drug could be considered for deletion from the essential medicines list entirely.
Nausea and Vomiting Are Common
Tamiflu reliably causes stomach problems. In clinical trials, 9.9% of people taking Tamiflu experienced nausea compared to 6.2% on placebo, and 8% had vomiting compared to 3.3% on placebo. That means vomiting is roughly twice as likely when you take the drug. For someone already miserable with the flu, adding more nausea and vomiting in exchange for getting better 17 hours sooner is a trade-off that doesn’t always feel worth it.
Neuropsychiatric Side Effects in Children
This is the concern that generates the most fear. The FDA identified reports of unusual neurologic and psychiatric events in children 16 and younger, including delirium, hallucinations, confusion, abnormal behavior, convulsions, and encephalitis. Twelve pediatric deaths were reported after the drug’s approval, all in Japanese children.
One study looking at children taking Tamiflu as a preventive measure found neuropsychiatric side effects in roughly one out of five children, with sleep problems being the most common. A separate study put the overall incidence of neuropsychiatric symptoms at under 13%, mostly sleeping difficulties, dizziness, and headache.
The FDA reviewed these reports and concluded that the elevated numbers from Japan were most likely related to higher awareness of flu-related brain inflammation in that country, broader access to Tamiflu, and intensive monitoring that captured more adverse events. In other words, the FDA believes the flu itself, not the drug, likely caused many of these episodes. Still, the reports were concerning enough that the FDA required updated warning labels, and the possibility of a drug-related contribution has never been fully ruled out. Parents understandably find this unsettling.
The 48-Hour Window Is Tight
Tamiflu is only approved for people who have been symptomatic for two days or less. The FDA label states that efficacy in patients who begin treatment after 40 hours of symptoms “has not been established.” This creates a practical problem: many people don’t see a doctor within the first day or two of flu symptoms, especially if they initially assume they have a cold. By the time they get a prescription, the window may have closed, and the already-modest benefit shrinks further or disappears.
It Can Interfere With the Nasal Flu Vaccine
If you or your child received the nasal spray flu vaccine (the live attenuated version), Tamiflu can interfere with the immune response the vaccine is trying to build. The general guidance is to wait at least 48 hours after stopping Tamiflu before getting the nasal vaccine, and to wait at least two weeks after receiving the nasal vaccine before starting Tamiflu. If the timing overlaps, revaccination may be necessary. This doesn’t apply to the standard flu shot, which uses inactivated virus.
Resistance Is Low but Not Zero
Nearly all recently circulating flu strains in the United States remain susceptible to Tamiflu. However, a specific genetic mutation called H275Y can make the H1N1 strain of influenza completely resistant to the drug. When this mutation is present, Tamiflu is ineffective. Other mutations in circulating viruses have shown reduced susceptibility in lab tests, though not all of these translate to clinical resistance. The concern isn’t today’s resistance levels but the possibility that widespread use could push those numbers higher over time.
The Cost Relative to the Benefit
A standard five-day course of generic oseltamivir runs $100 to $160 at full retail price without insurance. With a discount coupon, that drops to $25 to $55. Even at the lower end, paying $25 or more to feel better roughly 17 hours sooner, while taking on a meaningful chance of nausea and vomiting, strikes many people as a poor deal. For high-risk patients (the elderly, immunocompromised individuals, pregnant women), the calculus may tip differently because the stakes of flu complications are higher. But for otherwise healthy adults and children, the cost-benefit ratio is genuinely debatable.
Who Might Still Benefit
None of this means Tamiflu is useless. For people hospitalized with severe influenza, or those at high risk of dangerous complications, even a modest reduction in symptom duration and viral load can matter. The WHO’s updated position reflects this: reserve it for serious cases rather than prescribing it broadly for every flu diagnosis. The drug isn’t “bad” in the sense of being harmful for most people. It’s “bad” in the sense that its benefits are far more limited than its reputation suggests, its side effects are real, and for the average healthy person with the flu, it often isn’t worth the cost or the stomach upset.